{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:14:37Z","timestamp":1778181277851,"version":"3.51.4"},"reference-count":16,"publisher":"American Academy of Pediatrics (AAP)","issue":"Supplement_5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"<jats:p>Mutations in the ATP1A2 gene cause familial hemiplegic migraine type 2, alternating hemiplegia of childhood, and cerebellar function deficits, epilepsy, and mental retardation. These symptoms are likely related to glutamatergic hyperexcitability. Our patient is a 12-year-old boy with a history of complex partial seizures, attention-deficit\/hyperactivity disorder, and fine motor difficulty. During early childhood, he had episodes of a self-resolving right-sided hemiparesis and focal epilepsy. His seizures did not respond to several antiepileptic medications but stopped after he received valproate. His intermittent episodes of hemiplegia persisted. Additionally, he had pronounced bilateral fine motor impairment and significant executive deficits that gradually worsened. The whole exome sequencing revealed a de novo missense mutation in the ATP1A2 gene and a maternally inherited POLG gene mutation of unknown clinical significance. We hypothesized that glutamatergic excitotoxicity due to the ATP1A2 mutation contributed to the pathogenesis of our patient\u2019s condition. He was started on N-methyl-D-aspartate receptor antagonists (memantine and dextromethorphan), as well as coenzyme Q10. One year later, he showed significant improvement in sustained attention, learning efficiency, general cognitive efficiency, and fine motor dexterity. We postulate that N-methyl-D-aspartate receptor antagonists were effective for behavioral, cognitive, and cerebellar symptoms in our patient with ATP1A2 gene mutation.<\/jats:p>","DOI":"10.1542\/peds.2017-0852","type":"journal-article","created":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T08:35:25Z","timestamp":1522658125000},"page":"S390-S394","source":"Crossref","is-referenced-by-count":20,"title":["Clinical Benefit of NMDA Receptor Antagonists in a Patient With <i>ATP1A2<\/i> Gene Mutation"],"prefix":"10.1542","volume":"141","author":[{"given":"Keisuke","family":"Ueda","sequence":"first","affiliation":[{"name":"Division of Neurology, Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatema","family":"Serajee","sequence":"additional","affiliation":[{"name":"Division of Neurology, Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahm M.","family":"Huq","sequence":"additional","affiliation":[{"name":"Division of Neurology, Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2018,4,1]]},"reference":[{"issue":"9","key":"2021121022080503300_B1","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/ng.2358","article-title":"De novo mutations in ATP1A3 cause alternating hemiplegia of childhood.","volume":"44","author":"Heinzen","year":"2012","journal-title":"Nat Genet"},{"issue":"3","key":"2021121022080503300_B2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10048-004-0183-2","article-title":"A G301R Na+\/K+ -ATPase mutation causes familial hemiplegic migraine type 2 with cerebellar signs.","volume":"5","author":"Spadaro","year":"2004","journal-title":"Neurogenetics"},{"issue":"6","key":"2021121022080503300_B3","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ana.20134","article-title":"Alternating hemiplegia of childhood or familial hemiplegic migraine?: a novel ATP1A2 mutation.","volume":"55","author":"Swoboda","year":"2004","journal-title":"Ann Neurol"},{"issue":"5 pt 1","key":"2021121022080503300_B4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0022-3476(06)80003-X","article-title":"Alternating hemiplegia of childhood.","volume":"122","author":"Bourgeois","year":"1993","journal-title":"J Pediatr"},{"issue":"1","key":"2021121022080503300_B5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1207\/s15324826an1201_8","article-title":"Alternating hemiplegia of childhood: a study of neuropsychological functioning.","volume":"12","author":"Shafer","year":"2005","journal-title":"Appl Neuropsychol"},{"issue":"25","key":"2021121022080503300_B6","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.1523\/JNEUROSCI.1081-09.2009","article-title":"Glutamate transporter coupling to Na,K-ATPase.","volume":"29","author":"Rose","year":"2009","journal-title":"J Neurosci"},{"issue":"4","key":"2021121022080503300_B7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1212\/01.WNL.0000172638.58172.5a","article-title":"Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures.","volume":"65","author":"Jen","year":"2005","journal-title":"Neurology"},{"issue":"19","key":"2021121022080503300_B8","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1523\/JNEUROSCI.16-19-06125.1996","article-title":"Mitochondrial dysfunction is a primary event in glutamate neurotoxicity.","volume":"16","author":"Schinder","year":"1996","journal-title":"J Neurosci"},{"issue":"2","key":"2021121022080503300_B9","first-page":"166","article-title":"Memantine: a review of possible uses in child and adolescent psychiatry.","volume":"22","author":"Hosenbocus","year":"2013","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"issue":"8","key":"2021121022080503300_B10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2165\/11634390-000000000-00000","article-title":"The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence.","volume":"26","author":"Sani","year":"2012","journal-title":"CNS Drugs"},{"issue":"6","key":"2021121022080503300_B11","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/j.1471-4159.2006.03991.x","article-title":"The chemical biology of clinically tolerated NMDA receptor antagonists.","volume":"97","author":"Chen","year":"2006","journal-title":"J Neurochem"},{"key":"2021121022080503300_B12","doi-asserted-by":"crossref","first-page":"22047","DOI":"10.1038\/srep22047","article-title":"Glutamate-system defects behind psychiatric manifestations in a familial hemiplegic migraine type 2 disease-mutation mouse model.","volume":"6","author":"B\u00f8ttger","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"2021121022080503300_B13","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/NRL.0b013e3180f60bd8","article-title":"Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action.","volume":"13","author":"Werling","year":"2007","journal-title":"Neurologist"},{"issue":"3","key":"2021121022080503300_B14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1526-4610.2010.01793.x","article-title":"Prolonged sporadic hemiplegic migraine associated with a novel de novo missense ATP1A2 gene mutation.","volume":"51","author":"De Sanctis","year":"2011","journal-title":"Headache"},{"issue":"6","key":"2021121022080503300_B15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.braindev.2017.02.001","article-title":"Alternating hemiplegia of childhood: pharmacological treatment of 30 Italian patients.","volume":"39","author":"Pisciotta","year":"2017","journal-title":"Brain Dev"},{"issue":"3","key":"2021121022080503300_B16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.neulet.2010.10.064","article-title":"Flunarizine blocks voltage-gated Na+ and Ca2+ currents in cultured rat cortical neurons: a possible locus of action in the prevention of migraine.","volume":"487","author":"Ye","year":"2011","journal-title":"Neurosci Lett"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/141\/Supplement_5\/S390\/887486\/peds_20170852.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/141\/Supplement_5\/S390\/887486\/peds_20170852.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T07:34:15Z","timestamp":1639208055000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/141\/Supplement_5\/S390\/34512\/Clinical-Benefit-of-NMDA-Receptor-Antagonists-in-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,1]]},"references-count":16,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2018,4,1]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2017-0852","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,1]]}}}